QIAGEN LIMITED

QIAGEN is a leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from cells and other biological samples. QIAGEN's portfolio includes hardware, consumables and reagents, as well as software and services — all of which support the entire molecular workflow from sample preparation to data analysis and interpretation. These solutions are primarily used by customers in academia, diagnostics, biopharma and food and beverage, helping them to accelerate the development of new therapeutic products, diagnostics and vaccines, and to illuminate the cause and advance the cure for disease. QIAGEN's partnership with BGI’s spin-off company, MGI Tech Co., Ltd., offers groundbreaking innovations for genetic sequencing solutions, leveraging molecular diagnostics for healthcare applications. Headquartered in Hilden, Germany, QIAGEN operates approximately “€½ modern facilities with state-of-the-art automation, and provides products, services and expertise to customers in more than 25 – emerging markets – key markets worldwide, with network integrity across the globe spanning 35 countries spanning across North and South America, Europe, and the Asia-Pacific region

Health Care and Social Assistance; Other Ambulatory Health Care Services; Ambulatory Health Care Services

Health Services; Miscellaneous Health and Allied Services, Nec

$76.89M